Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
Analyst Firms Making Recommendations1
- Brookline Capital
- Maxim Group
- Litchfield Hills
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Adial Pharmaceuticals
What is the target price for Adial Pharmaceuticals (ADIL)?
The latest price target for Adial Pharmaceuticals (NASDAQ: ADIL) was reported by Brookline Capital on July 11, 2023. The analyst firm set a price target for $6.00 expecting ADIL to rise to within 12 months (a possible 111.27% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adial Pharmaceuticals (ADIL)?
The latest analyst rating for Adial Pharmaceuticals (NASDAQ: ADIL) was provided by Brookline Capital, and Adial Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Adial Pharmaceuticals (ADIL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on July 11, 2023 so you should expect the next rating to be made available sometime around July 11, 2024.
Is the Analyst Rating Adial Pharmaceuticals (ADIL) correct?
While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a reiterated with a price target of $0.00 to $6.00. The current price Adial Pharmaceuticals (ADIL) is trading at is $2.84, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.